Last reviewed · How we verify
Azacitidine associated with Valproic acid
Azacitidine associated with Valproic acid is a Hypomethylating agent Small molecule drug developed by Assistance Publique - Hôpitaux de Paris. It is currently in Phase 2 development for Acute myeloid leukemia (AML), Myelodysplastic syndromes (MDS).
Azacitidine is a hypomethylating agent that works by inhibiting DNA methyltransferases, leading to increased expression of tumor suppressor genes.
Azacitidine is a hypomethylating agent that works by inhibiting DNA methyltransferases, leading to increased expression of tumor suppressor genes. Used for Acute myeloid leukemia (AML), Myelodysplastic syndromes (MDS).
At a glance
| Generic name | Azacitidine associated with Valproic acid |
|---|---|
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Drug class | Hypomethylating agent |
| Target | DNA methyltransferases |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Azacitidine is a pyrimidine analog that incorporates into DNA and RNA, causing DNA hypomethylation. This results in the reactivation of silenced tumor suppressor genes, leading to cell cycle arrest and apoptosis in cancer cells. The combination with valproic acid, a histone deacetylase inhibitor, further enhances the therapeutic effect by promoting chromatin remodeling and gene expression.
Approved indications
- Acute myeloid leukemia (AML)
- Myelodysplastic syndromes (MDS)
Common side effects
- Myelosuppression
- Fatigue
- Nausea
- Diarrhea
- Vomiting
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Azacitidine associated with Valproic acid CI brief — competitive landscape report
- Azacitidine associated with Valproic acid updates RSS · CI watch RSS
- Assistance Publique - Hôpitaux de Paris portfolio CI
Frequently asked questions about Azacitidine associated with Valproic acid
What is Azacitidine associated with Valproic acid?
How does Azacitidine associated with Valproic acid work?
What is Azacitidine associated with Valproic acid used for?
Who makes Azacitidine associated with Valproic acid?
What drug class is Azacitidine associated with Valproic acid in?
What development phase is Azacitidine associated with Valproic acid in?
What are the side effects of Azacitidine associated with Valproic acid?
What does Azacitidine associated with Valproic acid target?
Related
- Drug class: All Hypomethylating agent drugs
- Target: All drugs targeting DNA methyltransferases
- Manufacturer: Assistance Publique - Hôpitaux de Paris — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Acute myeloid leukemia (AML)
- Indication: Drugs for Myelodysplastic syndromes (MDS)
- Compare: Azacitidine associated with Valproic acid vs similar drugs
- Pricing: Azacitidine associated with Valproic acid cost, discount & access